Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Pharmacy Profile · Updated 2026-06-19

Medivera Compounding Pharmacy

Medivera Compounding Pharmacy is a PCAB-accredited 503A compounding pharmacy based in Springfield, Missouri. Operates under Missouri Board of Pharmacy oversight and dispenses patient-specific peptide preparations.

503A CompoundingSpringfield, MOFounded 2014
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19

About Medivera Compounding Pharmacy

Medivera Compounding Pharmacy is a PCAB-accredited 503A compounding pharmacy based in Springfield, Missouri. Operates under Missouri Board of Pharmacy oversight and dispenses patient-specific peptide preparations.

Medivera Compounding Pharmacy at a glance

Type
503A Compounding
Headquarters
Springfield, MO
Founded
2014
Licensure
Multi-state (verify per shipment)

Accreditations & quality

PCABUSP <797>Missouri Board of Pharmacy

What Medivera Compounding Pharmacy does

Compounds sterile injectable preparations including semaglutide and tirzepatide on a patient-specific 503A basis. USP <797> sterile compounding workflow.

Transparency

Pharmacy license and PCAB accreditation publicly verifiable. Quality documentation provided on request.

Patient-reported quality signals

Through US Telehealth Review's review of NexLife users, patients reported high quality medication delivered from reputable pharmacies. Specific signals patients valued and verified:

Used by which providers?

Medivera Compounding Pharmacy is part of NexLife's pharmacy network for compounded semaglutide.

Verifying Medivera Compounding Pharmacy

Other pharmacies

All 6 pharmacy partners →

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing